The FDA approval of daraxonrasib is a milestone in oncology, transforming a growth driver into a potentially treatable ...

Study of breast cancer survivors shows that depression and stress, rather than cardiac function decline, are the primary ...

Weighing a harder early adjustment period against that benefit is an ongoing, individualized conversation, she says, with no one-size-fits-all answer in an era of precision medicine. Her takeaway for ...

Monotherapy remains worth considering for patients who live far from a cancer center or who are older or more frail, for whom combination treatment may be too demanding, says Amanda Edmond, PA-C, of ...

Many patients require a dose interruption or reduction, and MARIPOSA showed efficacy remained consistent despite modifications, so Edmond treats dosing as adaptable and works to find the right dose ...

Early COPERNICUS results show subcutaneous amivantamab and proactive VTE and skin prophylaxis sharply reduce reactions, helping NSCLC patients stay on therapy. Amanda Edmond, PA-C, of Banner MD ...

FDA approves rusfertide (Mimrylo), a first-in-class hepcidin mimetic that regulates iron to control erythrocytosis in ...

FDA approves BESREMi (ropeginterferon alfa-2b-njft) as the first new treatment option for essential thrombocythemia in nearly ...

Surbhi Sidana, MD, discusses how the FDA-approved oral CELMoD iberdomide expands access and impacts nursing care in multiple ...

Oncology nurses share high-level strategies for advanced RCC therapy, focusing on managing hypertension, diarrhea, and ...

A new study shows physical activity increases tumor-killing T cells and reduces suppressive Tregs in obese lung environments, ...

Having recently moderated a case-based roundtable discussion on triple-negative breast cancer, Iorio shares her clinical ...